Johnson & Johnson, Cardinal Health, and other makers and distributors of opioid painkillers must face lawsuits claiming they banded together to wrongfully push sales of the addictive pills, a judge ruled as the first federal trial over the medicines looms next month.
U.S. District Judge Dan Polster ruled Tuesday that juries must decide whether to hold companies like pharmacy chain Walgreens Boots Alliance liable for undertaking “coordinated efforts” to commit “unlawful acts” in the marketing, delivering, and selling of opioids.
The ruling clears the way for J&J, Cardinal Health, Walgreens and other companies to face a federal court jury in Cleveland Oct. 21 on claims—by more than 2,000 U.S. cities and counties—they fueled an opioid crisis that kills more than 100 Americans daily.
The companies were seeking to throw out the municipalities’ civil-conspiracy claims and other allegations, but the judge refused. Based on the cities’ and counties evidence, “the court cannot conclude that no reasonable jury could find” opioid makers such as J&J and Teva Pharmaceutical Industries Ltd “entered into a conspiratorial agreement or malicious combination,” Polster wrote in a 10-page decision.
Local governments in hard-hit states including Ohio, West Virginia, and Kentucky have accused opioid makers, distributors, and pharmacy chains of understating the risks of prescription opioids, overstating their benefits, failing to halt suspiciously large shipments, and ignoring red-flags about repeated retail sales.
$150 Billion
The municipalities, along with nearly all the states, are seeking to hold the companies liable for billions of dollars spent dealing with the societal fallout from opioid addictions and overdoses. Some analysts say a final global settlement could cost pharma companies more than $150 billion.
Jessica Castles-Smith, a J&J spokeswoman, didn’t immediately return an email seeking comment. Officials of Cardinal Health and Walgreens also didn’t immediately return emails.
In his ruling, Polster said cities and counties found evidence that J&J’s Janssen unit, Teva, and Purdue Pharma LP set up a joint campaign in 2013 to coordinate efforts to market opioid painkillers and “exploit a decade of pain.”
That year, the companies “started a collaborative marketing strategy” that relied on paid speakers and front groups to drum up prescriptions for opioid painkillers, Polster said, summarizing the claims.
Local governments also have uncovered evidence that distributors such as Cardinal Health worked with pharmacy chains to insure the flow of opioid painkillers remained uninterrupted by regulators’ actions.
Advance Notice
“Between 2012 and 2016, Cardinal and Walgreens agreed to manipulate the timing and delivery of opioid orders,” Polster wrote in his review of the evidence. Cardinal officials also “provided advance notice to Walgreens of due diligence site visits, in order to avoid reporting suspicious orders to the DEA,” he said.
When Walgreens executives learned in 2013 that the U.S. Drug Enforcement Administration might shutter one of its Ohio distribution centers, they started working with officials at Mallinckrodt, another opioid distributor, “to reroute Walgreens’s opioid supply through other distributors” to keep pharmacy shelves stocked, Polster wrote.
“A reasonable jury could review the record evidence and find that distributor defendants shared a general conspiratorial objective, with themselves and with other defendants, to expand the opioid market and disregard regulatory obligations in order to achieve that goal,” the judge wrote.
Purdue has offered to resolve all its opioid litigation for more than $11 billion.
More must-read stories from Fortune:
—How the maker of the world’s bestselling drug keep prices sky-high
—Laundry pod exposures are rising for the first time since 2015
—This company will provide genetic counseling for a million person NIH study
—FCC: There is “overwelming support” for a 911-like suicide prevention hotline
—Listen to our audio briefing, Fortune 500 Daily
Follow Fortune on Flipboard to stay up-to-date on the latest news and analysis.
